257 related articles for article (PubMed ID: 23900794)
1. Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.
Lazaro G; Smith C; Goddard L; Jordan N; McClelland R; Barrett-Lee P; Nicholson RI; Hiscox S
Endocr Relat Cancer; 2013 Oct; 20(5):691-704. PubMed ID: 23900794
[TBL] [Abstract][Full Text] [Related]
2. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
3. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
4. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
6. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
Yang Z; Barnes CJ; Kumar R
Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
[TBL] [Abstract][Full Text] [Related]
7. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA
Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579
[TBL] [Abstract][Full Text] [Related]
8. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
Seoane S; Montero JC; Ocaña A; Pandiella A
J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Browne BC; Eustace AJ; Kennedy S; O'Brien NA; Pedersen K; McDermott MS; Larkin A; Ballot J; Mahgoub T; Sclafani F; Madden S; Kennedy J; Duffy MJ; Crown J; O'Donovan N
Breast Cancer Res Treat; 2012 Dec; 136(3):717-27. PubMed ID: 23117852
[TBL] [Abstract][Full Text] [Related]
11. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
12. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.
Hiscox S; Barnfather P; Hayes E; Bramble P; Christensen J; Nicholson RI; Barrett-Lee P
Breast Cancer Res Treat; 2011 Feb; 125(3):659-69. PubMed ID: 20354780
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
15. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
Kunisue H; Kurebayashi J; Otsuki T; Tang CK; Kurosumi M; Yamamoto S; Tanaka K; Doihara H; Shimizu N; Sonoo H
Br J Cancer; 2000 Jan; 82(1):46-51. PubMed ID: 10638965
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.
Wang SE; Xiang B; Zent R; Quaranta V; Pozzi A; Arteaga CL
Cancer Res; 2009 Jan; 69(2):475-82. PubMed ID: 19147560
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
[TBL] [Abstract][Full Text] [Related]
18. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab.
Chen JL; Wang JY; Tsai YF; Lin YH; Tseng LM; Chang WC; King KL; Chen WS; Chiu JH; Shyr YM
Menopause; 2013 Jun; 20(6):646-54. PubMed ID: 23340260
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
